Silo Pharma, Inc.
SILOSilo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research to treat underserved conditions.
Table of contents
Earnings
Next report
Sep 2, 2026 (in a month)Competitors
Profile
Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research to treat underserved conditions. The company develops novel therapies for central nervous system diseases, chronic pain, and mental health disorders such as PTSD and Alzheimer's. Additionally, the company maintains a cryptocurrency treasury strategy, holding and staking digital assets to generate yield.
An early-stage developer leveraging the 505(b)(2) regulatory pathway and academic partnerships to expedite the commercialization of repurposed and novel CNS therapies.
Questions, answered.
- What is Silo Pharma, Inc.'s market cap?
- Silo Pharma, Inc. (SILO) has a market capitalization of $334.0K and trades on NASDAQ.
- Who are Silo Pharma, Inc.'s competitors?
- Silo Pharma, Inc.'s key competitors include Atai Life Sciences, Enveric Biosciences, Inc. Common Stock, Minerva Neurosciences, Inc, and others. These companies compete in similar markets and product categories.
- Who does Silo Pharma, Inc. partner with?
- Silo Pharma, Inc.'s notable partners include Columbia University, University of Maryland, Baltimore, Medspray Pharma BV, and others.
- What subsidiaries does Silo Pharma, Inc. have?
- Silo Pharma, Inc.'s subsidiaries include Silo Pharma Inc. (Florida).
- Where is Silo Pharma, Inc. headquartered?
- Silo Pharma, Inc. is headquartered in United States of America and employs approximately 3 people. It has been publicly traded since 2012.